Juliana Cristina Santiago Bastos

Mrs. Juliana Cristina Santiago Bastos


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2013 in Viruses
Verified
Journal Article
Open access
PDF file
JBJuliana Cristina Santiago Bastos
Juliana Cristina Santiago Bastos
LKLuciana Kohn
Luciana Kohn
FFFabiana Fantinatti-Garboggini
Fabiana Fantinatti-Garboggini
MPMarina Aiello Padilla
Marina Aiello Padilla
EFEduardo Furtado Flores
Eduardo Furtado Flores
CAClarice Weis Arns
Clarice Weis Arns
The Hepatitis C virus causes chronic infections in humans, which can develop to liver cirrhosis and hepatocellular carcinoma. The Bovine viral diarrhea virus is used as a surrogate model for antiviral assays for the HCV. From marine invertebrates and microorganisms isolated from them, extracts were prepared for assessment of their possible antiviral activity. Of the 128 tested, 2 were considered active and 1 was considered promising. The best result was obtained from the extracts produced from the Bacillus sp. isolated from the sponge Petromica citrina. The extracts 555 (500 µg/mL, SI>18) and 584 (150 µg/mL, SI 27) showed a percentage of protection of 98% against BVDV, and the extract 616, 90% of protection. All of them showed activity during the viral adsorption. Thus, various substances are active on these studied organisms and may lead to the development of drugs which ensure an alternative therapy for the treatment of hepatitis C.

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JBJuliana Cristina Santiago Bastos
Juliana Cristina Santiago Bastos
MPMarina Aiello Padilla
Marina Aiello Padilla
LCLeonardo Cardia Caserta
Leonardo Cardia Caserta
NMNoelle Miotto
Noelle Miotto
AVAline Gonzalez Vigani
Aline Gonzalez Vigani
CAClarice Weis Arns
Clarice Weis Arns
Despite advances in therapy, hepatitis C virus (HCV) infection remains an important global health issue. It is estimated that a significant part of the world population is chronically infected with the virus, and many of those affected may develop cirrhosis or liver cancer. The virus shows considerable variability, a characteristic that directly interferes with disease treatment. The response to treatment varies according to HCV genotype and subtype. The continuous generation of variants (quasispecies) allows the virus to escape control by antivirals. Historically, the combination of ribavirin and interferon therapy has represented the only treatment option for the disease. Currently, several new treatment options are emerging and are available to a large part of the affected population. In addition, the search for new substances with antiviral activity against HCV continues, promising future improvements in treatment. Researchers should consider the mutation capacity of the virus and the other variables that affect treatment success.

6 December 2017 in Journal of Clinical Virology
Verified
Journal Article
Closed access
EWElinara Wollmeister
Elinara Wollmeister
AAAlfonso Eduardo Alvarez
Alfonso Eduardo Alvarez
JBJuliana Cristina Santiago Bastos
Juliana Cristina Santiago Bastos
FMFernando Augusto Lima Marson
Fernando Augusto Lima Marson
JRJosé Dirceu Ribeiro
José Dirceu Ribeiro
ARAdriana Gut Lopes Riccetto
Adriana Gut Lopes Riccetto

11 July 2013 in Viruses
Verified
Journal Article
Open access
PDF file
JBJuliana Cristina Santiago Bastos
Juliana Cristina Santiago Bastos
LKLuciana Kohn
Luciana Kohn
FFFabiana Fantinatti-Garboggini
Fabiana Fantinatti-Garboggini
MPMarina Aiello Padilla
Marina Aiello Padilla
EFEduardo Furtado Flores
Eduardo Furtado Flores
CAClarice Weis Arns
Clarice Weis Arns
The authors wish to add the following Acknowledgments and completed Table 1 to their paper published in Viruses [1], doi:10.3390/v5051219, website: http://www.mdpi.com/1999-4915/5/5/1219.